Skip to content

Potency of Topical Corticosteroids in Combination Preparations

Evaluation of Topical Corticosteroids Potency in Combination Preparations in Healthy Volunteers

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03606954
Enrollment
20
Registered
2018-07-31
Start date
2018-11-30
Completion date
2019-04-30
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Toxicity

Brief summary

Several combination topical drugs are available on the market. The potency of corticosteroids depends on a particular molecular structure and the skin penetration properties. Besides molecular structure, a penetration of a corticosteroid molecule correlates with physical properties of the vehicle which depend on physical properties of the vehicle constituents. Vasoconstriction assay is considered as the gold standard for testing potency of topical corticosteroids.

Detailed description

Primary outcome: Change in Vasoconstriction index following application of topical corticosteroids that are incorporated with or without an antibiotic and/or antifungal drugs in healthy volunteers.

Interventions

COMBINATION_PRODUCTCombination topical corticosteroid

Comparison of a vasoconstriction index between the 2 study arms

Sponsors

Soroka University Medical Center
CollaboratorOTHER
Ben-Gurion University of the Negev
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

double-blind controlled comparative study

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* No prior history of internal diseases that required vaccine-suppressing treatments * Absence of an active skin disease.

Exclusion criteria

* Treatment with topical corticosteroids in the 4 weeks prior to the study * Immune-suppressive treatment in the 4 weeks prior to the study * Pregnancy or breast feeding

Design outcomes

Primary

MeasureTime frameDescription
Vasoconstriction Index (VI) measured by Skin Color Reflectometry24 hoursVI change following application topical corticosteroids that are incorporated with an antibiotic and/or antifungal drugs.

Contacts

Primary ContactRaed Khoury, MD
raedkhoury1@hotmail.com0507905159
Backup ContactAlex Zvulunov, MD
azvulun@bgu.ac.il

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026